Emirates News Agency – NYUAD completes research study for cancer treatment with proteins

ABU DHABI, June 28, 2021 (WAM) – A new study by an international team of researchers, led by NYU Abu Dhabi Associate Professor of Biology Mazin Magzoub, provides important insight into the protein p53, an often mutated essential tumor suppressor and inactivated in cancer and a key target in the development of anticancer therapies.

In the article entitled “Protein mimetic amyloid inhibiting potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function”, published in the journal Nature Communications, researchers from Magzoub Lab, as well as colleagues from NYUAD, presented the process of use of mimetic proteins. to reactivate p53.

The team first screened a library of protein mimetics originally designed to target Alzheimer’s disease and type II diabetes. The screen identified a mimetic protein that powerfully dissociates mutant p53 aggregates and prevents re-aggregation of the protein. The researchers then demonstrated that the dissociation of the mutant p53 aggregates by the mimetic protein restores the tumor suppressor function of p53, resulting in the death of a wide range of cancer cells.

It is important to note that treatment with the mimetic protein effectively reduces tumors which harbor the p53 mutant, while exhibiting no noticeable toxicity to healthy tissue, thus greatly prolonging survival.

“With the increasing incidence of cancer around the world, there is an urgent need for new cancer treatments to complement or supplant current treatments,” Magzoub said.

“Here, we have demonstrated the first successful application of a true small molecule amyloid inhibitor as an anticancer agent. We believe this work will have a broad impact as it effectively bridges amyloid disease and cancer, providing a basis for informational approaches in the design of new and potent therapeutic cancer mutants targeting p53. “

WAM / Rola Alghoul / Amjad Saleh

Source link

Paul N. Strickland

Leave a Reply

Your email address will not be published. Required fields are marked *